Opportunities for Growth and Breakthroughs for Cell and Gene Therapies

“Current therapeutic platforms are nascent, developed in academic labs, challenged by the ability to efficiently scale, replicate, and effectively manufacture their therapies. While the science behind these platforms will need to change over time, regulators need to keep pace. Close collaboration with regulators is required to develop a path to approval. Manufacturing solutions for advanced therapies require seamless and robust tech transfer processes to avoid delays in process development and inefficient scale-up models; this is a current gap that needs to be addressed.”

-Emily Moran, Vice President of Vector Manufacturing at Center for Breakthrough Medicines

Read full story